SS
GLUE icon

SBI Securities’s Monte Rosa Therapeutics GLUE Stock Holding History

SBI Securities’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.82K Sell
232
-6
-3% -$115 ﹤0.01% 2139
2025
Q4 		$3.73K Sell
238
-80
-25% -$1.08K ﹤0.01% 2145
2025
Q3 		$2.36K Buy
318
+48
+18% +$254 ﹤0.01% 2361
2025
Q2 		$1.22K Sell
270
-412
-60% -$1.84K ﹤0.01% 2591
2025
Q1 		$3.16K Buy
682
+30
+5% +$184 ﹤0.01% 2085
2024
Q4 		$4.53K Buy
+652
New +$4.89K ﹤0.01% 1961

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

SBI Securities's GLUE Position: Q1 2026 in Review

SBI Securities reduced its Monte Rosa Therapeutics (GLUE) stake by 2.5% in Q1 2026, selling an estimated $115 and leaving 232 shares worth $3.82K. The position accounts for ﹤0.01% of the portfolio, ranked #2139.

SBI Securities first reported a position in GLUE in Q4 2024 and has held it in 6 quarters since. The position peaked at $4.53K in Q4 2024. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • SBI Securities held 232 shares of Monte Rosa Therapeutics worth $3.82K as of Q1 2026.
  • SBI Securities sold 6 Monte Rosa Therapeutics shares in Q1 2026, an estimated $115.
  • Monte Rosa Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q1 2026, its #2139 holding.
  • SBI Securities first reported a position in Monte Rosa Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • SBI Securities's Monte Rosa Therapeutics position peaked at $4.53K in Q4 2024.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on SBI Securities's 13F filing for Q1 2026, filed 28 Apr 2026.